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USP <795>, <797>, and <800>
As of December 1, 2019, the Iowa Board of Pharmacy 
will require full compliance with United States Pharma-
copeia (USP) General Chapters <795>, <797>, and <800>. 
Compliance with USP Chapter <800> will be required for 
both compounding and non-compounding pharmacies (657 
Iowa Administrative Code (IAC) 8.5(11)). Compounding 
pharmacies that are unable to meet certain requirements 
within USP may apply to the Board to request a delay of 
the enforcement date. If granted, the maximum amount of 
time for delayed enforcement will be 18 months. Additional 
time extensions will not be permitted. 
Petitioners were required to submit a completed Delayed 
Compliance Petition Form and all required supporting 
documentation by September 1, 2019. Decisions will 
be made prior to the Board meeting scheduled for 
November 5-6, 2019; the potential exists for a requested 
appearance at this meeting if the application requires full 
Board approval. Please plan accordingly. 
Electronic Prescribing Mandate – 
January 1, 2020
In 2018, the Iowa Legislature passed legislation that will 
require all prescriptions, including controlled substances, to 
be electronically prescribed by prescribers and electronical-
ly received by pharmacies, beginning on January 1, 2020.
According to Surescripts data from July 2019, Iowa’s 
e-prescribing activity is still well below the national aver-
ages. Of   Iowa’s prescribers, 67.6% (versus 75% nationally) 
are submitting electronic prescriptions to pharmacies. A 
total of  64.1% of  Iowa’s prescribers have certified and 
audit-approved software that is capable of  transmitting 
electronic prescriptions for controlled substances (EPCS). 
Yet, only 38.6% of Iowa’s prescribers have enabled this 
feature within their e-prescribing software (versus 38% 
nationally). 
Conversely, Iowa’s pharmacies are on par with the 
national average for the ability to receive electronic 
prescriptions (both are 98.2%), while the rate of  EPCS-
enabled pharmacies in Iowa hedges out the national averages 
by just over 2% (97.9% versus 95.3%, respectively).
The legislation requiring e-prescribing permitted several 
exceptions to the e-prescribing mandate. Prescriptions that 
are excluded from the mandate include:
1. A prescription for a patient residing in a nursing 
home, long-term care facility, correctional facility, 
or jail.
2. A prescription authorized by a licensed veterinarian.
3. A prescription dispensed by a US Department of 
Veterans Affairs pharmacy.
4. A prescription requiring information that makes elec-
tronic submission impractical, such as complicated 
or lengthy directions for use or attachments.
5. A prescription for a compounded preparation con-
taining two or more components.
6. A prescription issued in response to a public health 
emergency in a situation where a non-patient-specific 
prescription would be permitted.
7. A prescription issued pursuant to an established and 
valid collaborative practice agreement, standing 
order, or drug research protocol.
8. A prescription issued during a temporary technical or 
electronic failure at the practitioner’s or pharmacy’s 
location, provided that a prescription issued pursuant 
to this exception shall indicate on the prescription 
that the practitioner or pharmacy is experiencing a 
temporary technical or electronic failure.
9. A prescription issued in an emergency situation pur-
suant to federal law and regulation rules of  the Board.
Additionally, a practitioner, medical group, or pharmacy 
that is unable to timely comply with the electronic 
prescribing requirements may petition the Board for 
an exemption based on economic hardship; technical 
limitations that the practitioner, medical group, or pharmacy 
prosecution, imprisonment, and revocation of their DEA 
numbers. The agency emphasizes that DEA will never 
contact practitioners by phone to demand money or any 
form of payment. DEA will not request any personal or 
sensitive information by phone, and notification of  le-
gitimate investigation or legal action is made via official 
letter or in person. 
DEA asks anyone who receives a call from a person 
purporting to be a DEA special agent or other law en-
forcement official asking for money to refuse the demand 
and report the threat using the online form or by calling 
877/792-2873. Reporting these calls will assist DEA in 
investigating and stopping this activity. 
FDA Officials Outline 2019 Efforts to 
Improve Quality of Compounded Drugs 
Recognizing the important roles compounded drugs 
can play in patient care, FDA plans to continue its efforts 
to improve the quality of compounded drugs. According 
to a statement posted to the FDA website, these priorities 
include: 
♦ maintaining quality manufacturing compliance,
♦ strengthening and refining regulations on com-
pounding from bulk drug substances,
♦ finalizing the agency’s memorandum of  understand-
ing with the states, and
♦ issuing revised draft guidance for compounding by
hospital and health systems.
“We’ve worked to refine our existing practices, shape 
new policies and increase the frequency of our com-
munications with industry, Congress, states and patients 
concerning our programs,” then-Commissioner Scott 
Gottlieb, MD, and Deputy Commissioner Anna Abram 
said in a statement published on the FDA website. “We 
anticipate that 2019 will be an equally productive year 
for the FDA’s compounding program, with better quality 
continuing to be our top priority as part of our ongoing 
effort . . . to improve the quality of compounded products 
for consumers . . .”
In addition, Gottlieb and Abram’s statement notes that 
the agency will continue to work closely with stakehold-
ers on these steps and any other compounding-related 
measures not outlined in the statement.
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FDA Changes Opioid Labeling to 
Give Providers Better Information on 
Tapering
 Noting that the agency remains focused on striking 
the right balance between policies that reduce the rates of 
opioid addiction while still allowing patients and health 
care providers access to appropriate pain treatments, Food 
and Drug Administration (FDA) has announced required 
changes to the prescribing information for all opioid 
analgesic medications used in the outpatient setting. The 
changes, announced in a Drug Safety Communication, 
provide expanded information to health care providers 
on how to safely decrease the dose in patients who are 
physically dependent on opioids. FDA intends for this 
information to be used when health care providers and 
patients have decided together that a decrease in dose or 
discontinuation of opioids is appropriate. 
“Rapid discontinuation can result in uncontrolled 
pain or withdrawal symptoms. In turn, these symptoms 
can lead patients to seek other sources of opioid pain 
medicines, which may be confused with drug-seeking for 
abuse,” the agency said in the communication. “Patients 
may attempt to treat their pain or withdrawal symptoms 
with illicit opioids, such as heroin, and other substances.”
In addition to these changes, an FDA press release also 
announced that additional policies related to the opioid 
crisis are forthcoming. These include a requirement for 
immediate-release formulations of opioids to be made 
available in fixed-quantity packaging that contain doses 
more typical of what patients may need for common 
acute pain conditions and procedures. The full press 
release is available in the News and Events section of 
the FDA website.
DEA Warns of Scam Calls Targeting 
Pharmacists and Other DEA-Registered 
Providers
Health care providers and other members of  the public 
have reported receiving phone calls from people claiming 
to represent Drug Enforcement Administration (DEA), 
and threatening legal action against them if a large fine 
is not paid immediately over the phone. According to 
a DEA press release, this scam used fake names and 
badge numbers, or the names of  well-known senior 
officials with DEA, and threatened victims with arrest, 
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China Agrees to Stricter Fentanyl 
Production Laws Following Pressure 
From US Lawmakers 
China has announced that all variations of the power-
ful opioid product, fentanyl, will be treated as controlled 
substances (CS). According to a press release from 
Senator Tom Cotton, the announcement came after a 
bipartisan group of  United States lawmakers, including 
Cotton, introduced Senate Bill 1044, a bill designed to 
apply pressure to the Chinese government to make all 
forms of  synthetic opioids illegal and to provide US law 
enforcement with more tools and resources to go after 
illicit traffickers in China, Mexico, and other countries. 
“Combating the flow of  illicit fentanyl into our coun-
try is imperative in the fight to save American lives 
from the opioid crisis,” Senate Minority Leader Chuck 
Schumer said in the press release. “We must hold China 
accountable for their role in the fentanyl trade. China’s 
new regulation to make all fentanyl categories illegal is 
an important step and the administration deserves praise 
for their efforts to secure this change. However, we have 
to demonstrate that we will demand China enforce these 
laws and take strong action against opioid traffickers.”
In a December meeting with President Donald Trump, 
China’s President Xi Jinping promised to classify fen-
tanyl as a CS following a 2018 report by the US-China 
Economic and Security Review Commission that found 
China to be “the largest source of  illicit fentanyl and 
fentanyl-like substances” in the US, according to a report 
from NPR. The latest increase in opioid-related overdose 
deaths has been largely attributed to the availability of 
illegally manufactured fentanyl.
Two Lots of Transdermal Fentanyl 
Patches Recalled Due to Product 
Mislabeling
Alvogen, Inc, of  Pine Brook, NJ, is recalling two lots 
of Fentanyl Transdermal System 12 mcg/h transdermal 
patches to the consumer level after a small number of 
cartons were found to contain 50 mcg/h patches. Though 
the 50 mcg/h patches are individually labeled correctly, 
accidental application of  the higher dosage patch instead 
of the prescribed 12 mcg/h patch could result in serious, 
life-threatening, or fatal respiratory depression. The 
company has not received any reports of adverse events 
related to this issue.
The company is notifying its distributors and direct 
customers by certified letter and is arranging for the return 
and replacement of  all recalled products. Pharmacies 
are asked to stop dispensing any product subject to the 
recall. Consumers that have affected products should im-
mediately remove any patch currently in use and contact 
their health care provider. Patients with unused product 
should return it to the point of  purchase for replacement. 
Additional information on the recall, including the 
affected lot numbers and customer service contact infor-
mation, is available in a press release posted to the FDA 
website. Adverse reactions and quality problems can be 
reported to the FDA MedWatch Safety Information and 
Adverse Event Reporting Program.
FDA Releases Toolkit to Help Promote 
Safe Opioid Disposal
FDA has made a new resource available for consumers 
and health care providers to help promote and educate 
individuals about how to safely dispose of unused opi-
oids. The free Safe Opioid Disposal – Remove the Risk 
Outreach Toolkit includes video, radio, and print public 
service announcements, social media graphics and posts, 
fact sheets, drop-in content, and website badges that 
health care providers and other interested individuals and 
organizations can use to promote the message of opioid 
safety. The toolkit and its resources can be accessed on 
the Ensuring Safe Use of  Medicine section of the FDA 
website.
An additional resource available to help consumers 
find disposal kiosks available year round is the National 
Association of Boards of Pharmacy® (NABP®) Drug 
Disposal Locator Tool, available in the AWARXE
® Pre-
scription Drug Safety section of  the NABP website, www 
.nabp.pharmacy/initiatives/AWARxE. With more than 
6,500 disposal sites in the continually updated database, 
consumers can enter location information to find the 
nearest disposal sites to them using a map. 
Additional information about the FDA campaign can 
be found at https://www.fda.gov/drugs/buying-using-
medicine-safely/ensuring-safe-use-medicine.
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cannot control; or other exceptional circumstances. The 
Board may grant exception requests for a period of  time 
that may not exceed one year, which may be renewable with 
Board approval. Exemption petition forms and additional 
information regarding the e-prescribing mandate can be 
found on the Board’s website.
After the mandate becomes effective on January 1, 
2020, a pharmacist who receives a written, oral, or 
faxed prescription that is otherwise legitimate will not 
be required to verify that the prescription is subject 
to an exception previously listed and may dispense the 
prescription. Failure to transmit a prescription as an elec-
tronic prescription does not automatically nullify or make 
the prescription “illegal.” However, a pharmacist must 
exercise professional judgment in identifying and reporting 
suspected violations of the e-prescribing mandate to either 
the Board or the appropriate professional licensing board 
of the practitioner. 
A prescriber who violates this mandate is subject to an 
administrative penalty of $250 per violation, up to a maxi-
mum of  $5,000 per calendar year. The administrative pen-
alty assessed by the prescriber’s primary licensing board 
will not be considered a disciplinary action or reported as 
discipline. A practitioner may appeal the assessment of 
the administrative penalty, which will initiate a contested 
case proceeding. The administrative penalties collected 
will be deposited into the drug information program fund 
to further support and enhance Iowa’s prescription moni-
toring program.
Statewide Protocols
The Board’s statewide protocols for naloxone, nicotine 
replacement products, and immunizations went into effect 
on April 5, 2019. Pharmacists acting under the statewide 
protocol may need to obtain a national provider identifica-
tion (NPI) number in order to properly bill the prescriptions 
to third-party payers. 
Additionally, the Iowa Legislature postponed the sun-
setting of  the physician-approved immunization protocols 
from July 1, 2019, to July 1, 2020. The legislature recog-
nized that additional time may be necessary to ensure that 
Iowa Medicaid recognizes the pharmacists’ NPI number 
on the claims being submitted for immunizations under 
the statewide protocol.
Technician Product Verification 
Programs
The Board adopted final rulemaking to rescind 
Chapter 40, “Tech-Check-Tech Programs” and adopt 
the new Chapter 40, “Technology-Assisted Technician 
Product Verification Programs.” During the 2018 session 
of the Iowa Legislature, the IAC was amended to allow 
technician product verification (TPV) programs in 
community pharmacies. Previous programs were called 
tech-check-tech programs and only authorized the 
practice in a hospital pharmacy or community pharmacy 
providing care for facility patients when another licensed 
health care practitioner would be administering the 
medications. Under the new rules, which became 
effective June 26, 2019, a pharmacy may establish a TPV 
program that is intended to redirect pharmacist time to 
increased clinical services (such as medication therapy 
management, collaborative practice, statewide protocols, 
and immunizations). In a pharmacy using a TPV 
program, pharmacist hours shall not be reduced but 
shall be redistributed to clinical pharmacy services 
to improve patient care and health outcomes.
Additional TPV program requirements shall include:
 ♦ appropriate scanning technology to ensure that each 
product is accurately filled and verified
 ♦ no more than three checking technicians per phar-
macist involved in the prescription-filling process 
(institutional settings are exempt)
 ♦ advance notice to the Board of program implemen-
tation
 ♦ minimum qualifications for checking technicians
 ♦ quality assurance process
◊ quarterly verification
◊ quarterly reports
 ♦ record keeping
The Board did not authorize “grandfathering” of 
any previously existing tech-check-tech programs, so 
pharmacies are expected to be compliant with the revised 
rules in Chapter 40, unless the pharmacy has received a 
waiver. The complete chapter is available on the Board’s 
website.
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